Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge.
Carlos Rodriguez-Galindo, Paola Friedrich, Patricia Alcasabas...
https://pubmed.ncbi.nlm.nih.gov/26304881Actively Recruiting
Age: 0Years - 21Years
All Genders
ID07246213
Improving Cancer Outcomes for Children, Adolescents, and Young Adults: A Multicenter Retrospective Cohort Study on Treatment Failure and Toxicity in Low- and Middle-Income Countries
Led by Resonance, Inc. · Updated on 2025-12-19
18000
Participants Needed
5
Research Sites
26 weeks
Total Duration
On this page
Sponsors
R
Resonance, Inc.
Lead Sponsor
S
Servier Affaires Médicales
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to assess cancer treatment outcomes in children, adolescents, and young adults aged 0 to 21 years living in low- and middle-income countries (LMICs). It focuses especially on acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL), which have poorer outcomes in these regions compared to high-income countries due to challenges like delayed diagnosis, limited access to therapies, and financial barriers. The study seeks to inform future efforts to improve care quality and reduce treatment failures through evidence-based strategies. The study involves a retrospective review of medical records from participating oncology centers in several LMICs, including Guatemala, Honduras, El Salvador, Armenia, and Tanzania. It includes patients with any cancer diagnosis, with particular attention to those diagnosed with ALL or LBL. Researchers will collect data on treatment failure incidence, therapy-related toxicities, and clinical outcomes over a three-year period following cancer diagnosis. No experimental treatments are administered; the study uses existing medical records for analysis. Participants' medical records will be reviewed to capture information on treatment failure, including relapse, progression, or abandonment, and therapy-related toxicities in the ALL/LBL subgroup. Researchers will also analyze outcomes by cancer type, treatment regimen, age, and sociodemographic factors. The primary outcomes include incidence of treatment failure and toxicities within three years of diagnosis. This observational study will provide valuable data to guide improvements in cancer care for young patients in LMICs.
CONDITIONS
Brief Title
CAYA Cancer Retrospective Cohort Study
Who Can Participate
Age: 0Years - 21Years
All Genders
Eligibility Criteria
You may qualify if you...
- Willing and able to provide informed consent or assent with guardian consent if underage
- Confirmed diagnosis of any type of cancer within 15 years before site activation
- Age between 0 and 21 years at the time of diagnosis
- Received substantial anti-cancer treatment at the participating center, such as chemotherapy, surgery, radiation, or immunotherapy
- Medical records are available and accessible for review
You will not qualify if you...
- Patients who only visited the participating center for consultation without primary anti-cancer treatment
- Patients who only had pathology, radiology, or other diagnostic evaluations without treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Surveillance
Duration - Up to 15 years retrospective data
Participants who underwent cancer treatment in the past have their medical records reviewed retrospectively to assess treatment failure, therapy-related toxicities, and clinical outcomes.
No visits; data is collected from existing medical records
Long-term Monitoring
Duration - 3 years retrospective follow-up
Participants’ treatment outcomes and toxicities are followed up retrospectively for up to 3 years from the date of cancer diagnosis via medical records to estimate incidence and survival.
No visits; follow-up through medical record review
Trial Site Locations
Total: 5 locations
1
Yeolyan Center for Cancer and Blood Disorders
Yerevan, Armenia
Actively Recruiting
2
Fundación Ayúdame a Vivir
El Salvador, El Salvador, El Salvador, 1101
Not Yet Recruiting
3
Unidad Nacional de Oncología Pediátrica (UNOP)
Guatemala City, Guatemala
Actively Recruiting
4
Hospital Mario Catarino Rivas
San Pedro Sula, Cortés Department, Honduras, 21102
Not Yet Recruiting
5
Hospital Escuela
Tegucigalpa, Distrito Central, Honduras, 11101
Not Yet Recruiting
Loading map...
Research Team
G
Gabriela Villanueva, MD.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Global efforts toward the cure of childhood acute lymphoblastic leukaemia.
Ching-Hon Pui, Jun J Yang, Nickhill Bhakta...
https://pubmed.ncbi.nlm.nih.gov/30169285Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
N Toft, H Birgens, J Abrahamsson...
https://pubmed.ncbi.nlm.nih.gov/28819280Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment.
Guillermo Chantada, Catherine G Lam, Scott C Howard
https://pubmed.ncbi.nlm.nih.gov/30740656The My Child Matters programme: effect of public-private partnerships on paediatric cancer care in low-income and middle-income countries.
Scott C Howard, Alia Zaidi, Xueyuan Cao...
https://pubmed.ncbi.nlm.nih.gov/29726390